CN1309381C - 用于治疗肿瘤的去甲二氢愈创木酸衍生物 - Google Patents

用于治疗肿瘤的去甲二氢愈创木酸衍生物 Download PDF

Info

Publication number
CN1309381C
CN1309381C CNB008160228A CN00816022A CN1309381C CN 1309381 C CN1309381 C CN 1309381C CN B008160228 A CNB008160228 A CN B008160228A CN 00816022 A CN00816022 A CN 00816022A CN 1309381 C CN1309381 C CN 1309381C
Authority
CN
China
Prior art keywords
ndga
derivant
purposes
tumor
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008160228A
Other languages
English (en)
Chinese (zh)
Other versions
CN1391471A (zh
Inventor
黄汝吉
乔纳森·D·赫勒
胡纪如
金克永
吴拉姆·侯塞因·哈基姆拉希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN1391471A publication Critical patent/CN1391471A/zh
Application granted granted Critical
Publication of CN1309381C publication Critical patent/CN1309381C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CNB008160228A 1999-10-15 2000-10-16 用于治疗肿瘤的去甲二氢愈创木酸衍生物 Expired - Lifetime CN1309381C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/418,594 US6214874B1 (en) 1999-10-15 1999-10-15 Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US09/418,594 1999-10-15

Publications (2)

Publication Number Publication Date
CN1391471A CN1391471A (zh) 2003-01-15
CN1309381C true CN1309381C (zh) 2007-04-11

Family

ID=23658774

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008160228A Expired - Lifetime CN1309381C (zh) 1999-10-15 2000-10-16 用于治疗肿瘤的去甲二氢愈创木酸衍生物

Country Status (10)

Country Link
US (4) US6214874B1 (https=)
EP (1) EP1231914B1 (https=)
JP (2) JP4062664B2 (https=)
CN (1) CN1309381C (https=)
AT (1) ATE350030T1 (https=)
AU (1) AU783015C (https=)
CA (1) CA2387873C (https=)
DE (1) DE60032795T2 (https=)
SG (1) SG144712A1 (https=)
WO (1) WO2001028494A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN103585136A (zh) * 2003-05-20 2014-02-19 约翰霍普金斯大学 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
BRPI0413182A (pt) * 2003-08-07 2006-10-03 Huntsman Adv Mat Switzerland poliuretano linear, composição, moldagem, material, processo para a produção de máscara de solda sobre um circuito impresso, e, uso da composição
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
ATE538778T1 (de) 2004-05-28 2012-01-15 Unigen Inc 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'- dihydroxyphenyl)-propan als hochwirksamer tyrosinase-inhibitor
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
CA2583336A1 (en) * 2004-10-06 2006-04-20 Johns Hopkins University Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2008088806A1 (en) * 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
ES2588235T3 (es) * 2007-05-11 2016-10-31 Convatec Technologies Inc. Dispositivo de ostomía
CA2730265C (en) * 2008-07-21 2016-06-28 Unigen, Inc. Series of skin-whitening (lightening) compounds
WO2010011117A2 (ko) * 2008-07-25 2010-01-28 국립암센터 Ｎｄｇａ를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
AU2012231008B2 (en) 2011-03-24 2017-05-11 Unigen, Inc. Compounds and methods for preparation of diarylpropanes
WO2012166778A2 (en) * 2011-05-31 2012-12-06 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
CN104603094A (zh) * 2012-07-18 2015-05-06 约翰霍普金斯大学 通过四-o-甲基去甲二氢愈创木酸抑制bnip3以及预防和治疗缺血再灌注损伤的方法
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
MX391317B (es) 2017-02-17 2025-03-21 Promotora Tecnica Ind S A De C V Composicion mejorada a base de acido norhidroguayaretico.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) * 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5646186A (en) * 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes

Also Published As

Publication number Publication date
AU783015C (en) 2006-08-24
US20030065016A1 (en) 2003-04-03
DE60032795T2 (de) 2007-11-08
WO2001028494A9 (en) 2002-08-01
SG144712A1 (en) 2008-08-28
JP2003511477A (ja) 2003-03-25
EP1231914B1 (en) 2007-01-03
JP4062664B2 (ja) 2008-03-19
WO2001028494A2 (en) 2001-04-26
EP1231914A4 (en) 2004-04-14
CA2387873C (en) 2008-12-30
WO2001028494A3 (en) 2002-01-10
AU783015B2 (en) 2005-09-15
US6214874B1 (en) 2001-04-10
CN1391471A (zh) 2003-01-15
CA2387873A1 (en) 2001-04-26
US20050267208A1 (en) 2005-12-01
ATE350030T1 (de) 2007-01-15
EP1231914A2 (en) 2002-08-21
US6958411B2 (en) 2005-10-25
AU1207501A (en) 2001-04-30
DE60032795D1 (de) 2007-02-15
HK1050860A1 (en) 2003-07-11
US6417234B1 (en) 2002-07-09
JP2008019278A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
CN1309381C (zh) 用于治疗肿瘤的去甲二氢愈创木酸衍生物
CN1525857A (zh) 用去甲二氢愈创木酸衍生物治疗肿瘤的方法
AU2002311890A1 (en) Method for treatment of tumors using nordihydroguaiaretic acid derivatives
JP2004534025A5 (https=)
CN1758905A (zh) 青蒿素在治疗致癌病毒诱导的肿瘤和治疗病毒感染中的应用
US12583850B2 (en) Small molecule antiviral drug treatment for human papillomavirus infections
HK1050860B (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
US6441009B1 (en) Agent and method of preventing and treating heavy metal exposure and toxicity
WO2022177908A1 (en) 2-s rimantadine and 2-r rimantadine for treating cancer and precancerous papilloma virus lesions
HK1062635A (en) Method for treatment of tumors using nordihydroguaiaretic acid derivatives
HK1062635B (en) Method for treatment of tumors using nordihydroguaiaretic acid derivatives
WO2004096276A9 (ja) 糖取り込み能増強剤
HK1090032A (en) Antitumor effect potentiator and antitumor agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1050860

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20070411

CX01 Expiry of patent term